Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.